Claudia Parisi, Praticienne Specialiste at Centre Antoine Lacassagne and Editorial Board Member at BMJ Oncology, shared a post on LinkedIn:
“Dear Colleagues,
I am writing to invite you to contribute to a new Special Issue that I am guest editing for Pharmaceutics, titled ‘Antibody–Drug Conjugates (ADCs) for cancer treatment: from mechanistic insights to clinical translation’.
Antibody–drug conjugates (ADCs) continue to transform oncology, with rapid advances in linker technologies, site-specific conjugation, payload development and biomarker-guided patient selection. This Special Issue aims to highlight current innovations, mechanistic insights, and translational challenges of ADCs across solid malignancies.
We are delighted to consider proposals for review papers and original articles on subjects including, but not limited to, the following:
Foundations and technological advances in ADCs design, including antibody engineering and target selection; linker chemistry and drug release innovations; conjugation manufacturing; payload discovery and mechanisms.
Biomarkers and precision patient selection.
Preclinical and translational development, including in vivo and ex vivo models; toxicity mechanisms and safety mitigation; interaction between ADCs and the immune system.
Clinical development and therapeutic applications. Future directions and transformative concepts, including industry and regulatory perspectives.
If you are interested in contributing, I would be pleased to discuss potential topics or provide any additional information.
Thank you very much for considering this invitation. I hope to have the opportunity to include your work in this Special Issue.
Dr. Claudia Parisi
Guest Editor.”
Other articles about ADCs on OncoDaily.